Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant Treatment of Patients With Stage II and III Luminal Breast Cancer [Estudio Fase II, abierto, no randomizado con nab-paclitaxel para el tratamiento neoadyuvante de pacientes con cáncer de mama luminal estadios II y III]

Trial Profile

Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant Treatment of Patients With Stage II and III Luminal Breast Cancer [Estudio Fase II, abierto, no randomizado con nab-paclitaxel para el tratamiento neoadyuvante de pacientes con cáncer de mama luminal estadios II y III]

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Early breast cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms Nabrax
  • Most Recent Events

    • 03 Jun 2014 Final efficacy and biomarker results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Jun 2014 Primary endpoint 'Objective-clinical-response-rate' has not been met.
    • 24 May 2014 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top